Sanctuary Advisors LLC Has $8.98 Million Stock Position in GSK plc (NYSE:GSK)

Sanctuary Advisors LLC trimmed its position in shares of GSK plc (NYSE:GSK - Free Report) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 254,072 shares of the pharmaceutical company's stock after selling 18,488 shares during the quarter. Sanctuary Advisors LLC's holdings in GSK were worth $8,984,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co grew its stake in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Eastern Bank bought a new position in GSK in the third quarter valued at approximately $26,000. Crews Bank & Trust bought a new position in GSK in the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. boosted its stake in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Sunbelt Securities Inc. boosted its stake in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock traded down $0.34 during midday trading on Friday, hitting $36.62. 5,644,657 shares of the company were exchanged, compared to its average volume of 4,666,008. The firm has a market capitalization of $75.91 billion, a P/E ratio of 23.03, a PEG ratio of 1.11 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm's 50 day moving average price is $34.55 and its two-hundred day moving average price is $37.38. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities research analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.29%. GSK's payout ratio is 93.08%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and cut their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.